Voyager Therapeutics (NASDAQ:VYGR) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research note released on Thursday morning,Benzinga reports. HC Wainwright currently has a $30.00 price objective on the stock.

Other research analysts have also issued reports about the stock. StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Sunday, November 10th. Leerink Partners began coverage on shares of Voyager Therapeutics in a research report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price target on the stock. Wedbush reduced their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. Finally, Leerink Partnrs upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Voyager Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.00.

Voyager Therapeutics Trading Down 9.3 %

VYGR opened at $5.64 on Thursday. The company has a fifty day simple moving average of $6.62 and a 200 day simple moving average of $7.50. The firm has a market cap of $308.11 million, a price-to-earnings ratio of 7.94 and a beta of 0.89. Voyager Therapeutics has a twelve month low of $5.59 and a twelve month high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. The business had revenue of $24.63 million during the quarter, compared to analyst estimates of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period last year, the business earned ($0.59) EPS. On average, analysts forecast that Voyager Therapeutics will post -1.2 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the sale, the insider now directly owns 86,001 shares in the company, valued at approximately $500,525.82. The trade was a 6.52 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.53% of the stock is owned by insiders.

Institutional Trading of Voyager Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in VYGR. Great Point Partners LLC acquired a new position in shares of Voyager Therapeutics in the 2nd quarter worth approximately $12,668,000. Erste Asset Management GmbH acquired a new position in shares of Voyager Therapeutics in the 3rd quarter worth approximately $6,192,000. Farallon Capital Management LLC grew its stake in shares of Voyager Therapeutics by 77.4% in the 1st quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company’s stock worth $21,339,000 after purchasing an additional 1,000,000 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Voyager Therapeutics by 27.8% in the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock worth $30,087,000 after purchasing an additional 702,030 shares during the last quarter. Finally, Armistice Capital LLC grew its stake in shares of Voyager Therapeutics by 11.3% in the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after purchasing an additional 528,000 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.